Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2016-03-18 18:10:57
Reporting Period:
Filing Date:
Accepted Time:
2016-03-18 18:10:57
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1245104 Globeimmune Inc GBIM Pharmaceutical Preparations (2834) 841353925
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1262327 Augustine Lawlor C/o Healthcare Ventures Llc
47 Thorndike Street, Suite B1-1
Cambridge MA 02141
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2016-03-18 11,000 $1.55 463,267 No 4 S Indirect By Partnership
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By Partnership
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.30 to $1.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote (1) to this Form 4.
  2. These securities are held of record by HealthCare Ventures VII, L.P. ("HCVVII"). HealthCare Partners VII, L.P. ("HCPVII") is the General Partner of HCVVII. Mr. Lawlor, a member of the Board of Directors of the Issuer, is a general partner of HCPVII and, as such, exercises shared voting and investment power with respect to the shares owned by HCVVII. Mr. Lawlor disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein and this report shall not be deemed an admission that he is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.